Neuroendocrine Tumor of Pancreas
7
3
4
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (7)
A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors
Patients With High-grade Pancreatic Neuroendocrine Tumors
Precision Radiotherapy Using MR-linac for Pancreatic Neuroendocrine Tumours in MEN1 Patients
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients
Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors
68Ga-DOTATOC Radio-Guided Surgery With β-Probe in GEP-NET
Related Studies of Imaging Features and Prognosis Between Pancreatic Neuroendocrine Tumors and Pancreatic Cancer